Innovative Medicines Canada warns critical research will be impacted if the government forces its members to implement required regulatory changes by July 1.
Organizations: | House of Commons Standing Committee, Innovative Medicines Canada, and Patented Medicines Prices Review Board |
Topics: | COVID-19, drug prices, and Patented Medicine Regulations |